drugset / Trial / NCT00210067

A Study in Subjects With Retinal Detachment

NCT00210067 ↗

Phase 1 Completed 14 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).

Timeline

Start
2001-05
Primary completion
2002-06
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject denufosol Other / unclassified — Intravitreal

Indications